Latest Breaking News On - Alain herrera - Page 1 : comparemela.com

Isofol Medical () : publishes interim report, January-March 2024

Isofol Medical () : publishes interim report, January-March 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Petter segelman lindqvistHelena taflinMagnus hurstSolasia pharmaSten nilssonAlain herreraLars lindChief executiveChief financialSegelman lindqvist

Nanobiotix : Notice ADSs agenda and summaries of resolutions – shareholders general meeting May 28, 2024

Nanobiotix : Notice ADSs agenda and summaries of resolutions – shareholders general meeting May 28, 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkNord pas de calaisFrance generalAnne marie graffinAnne juliette hermantVan rhijnAlain herreraLouis kayitalireGary phillipsCompany on euronext parisFrench financial markets authorityCompany notice of meetingCompany frenchLaws of the companyShareholder services

Nanobiotix : Notice RADSs agenda and summaries of resolutions – shareholders general meeting May 28, 2024

Nanobiotix : Notice RADSs agenda and summaries of resolutions – shareholders general meeting May 28, 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Nord pas de calaisNew yorkUnited statesFrance generalAnne marie graffinVan rhijnAlain herreraLouis kayitalireAnne juliette hermantGary phillipsCompany notice of meetingCompany frenchFrench financial markets authorityShareholder servicesLaws of the companyCompany notice of meeting on

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

Switzerland generalFrance generalT ai peiAlain herreraBiomunex pharmaceuticalsOnward therapeuticsChief medicalBispecific antibodyHematological malignanciesPhase 1 clinical trialImmune checkpointsIopharmaceutical companyBiomunex pharmaceuticalsDrug developmentSolid tumorsCancer treatment

NANOBIOTIX Announces the Availability of a Prospectus in

PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical.

Îe de franceUnited kingdomNew yorkUnited statesNeuilly sur seineFrance generalNord pas de calaisKepler cheuvreuxAlain herreraGary phillipsBrandon owensLigia vela reidAnne juliette hermantAnne marie graffinEnno spillnerPierre louis germain